<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260813070637N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-01</date_registration>
      <primary_sponsor>National University of Medical Sciences Pakistan</primary_sponsor>
      <public_title>Effect of Melatonin on Pain and Facial Sensation After Surgery for Cheekbone Fractures</public_title>
      <acronym></acronym>
      <scientific_title>Effect of melatonin on postoperative pain and sensory recovery following zygomaticomaxillary complex fractures</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2027-01-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/93496</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be randomly allocated in a 1:1 ratio to either the melatonin group (Group A) or placebo group (Group B) using a lottery method. Treatment assignments will be placed in sequentially prepared, sealed opaque envelopes to ensure allocation concealment, Blinding description: Participants will be blinded to treatment allocation. Melatonin and placebo tablets will be identical in appearance and will be administered in the same manner (10 mg orally at bedtime), with both groups receiving treatment for 15 days.

The principal investigator and surgeon performing the zygomaticomaxillary complex fracture fixation will not be involved in allocation concealment or postoperative outcome assessment. Treatment allocation will be performed by lottery using sealed opaque envelopes.

The treating surgeon and healthcare providers involved in routine preoperative care will not be informed of the treatment allocation unless knowledge is required for patient safety.

The outcome assessor (dentist performing the visual analogue scale assessment and pin-prick sensory testing on postoperative day 7) will be blinded to treatment allocation. The assessor will not have access to the randomisation record or medication assignment.

Data analysis will be performed using coded groups (e.g., Group A and Group B) so that the statistician/data analyst is unaware of which group received melatonin until the primary analysis is completed. The treatment code will be revealed after completion of the analysis.

The study does not involve a separate Data Safety and Monitoring Board. Manuscript writers will use coded group data and will remain unaware of the treatment identity during preparation of the initial analysis and manuscript, where feasible.

Thus, the study will use concealed allocation with blinded participants, outcome assessor, and data analyst, while the operating surgeon and routine healthcare providers will not participate in outcome assessment.</study_design>
      <phase>2</phase>
      <hc_freetext>Zygomaticomaxillary complex fractures with infraorbital nerve sensory disturbance and postoperative pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Melatonin 10 mg orally at bedtime for 15 days, starting 60–90 minutes before surgery. Intervention 2: Control group: Placebo 10 mg orally at bedtime for 15 days, starting 60–90 minutes before surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is The study involves a relatively small participant population and sharing individual level data may pose a risk of participant re identification despite de identification</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Rana Talha Ahmad Khan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Combined Military Hospital, Rawalpindi cantt, Rawalpindi</address>
        <city>Rawalpindi</city>
        <country1>Pakistan</country1>
        <zip>46000</zip>
        <telephone>+92 323 6644244</telephone>
        <email>talha.doc244@gmail.com</email>
        <affiliation>Armed Forces Institute of Dentistry, Rawalpindi</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Saad Mehmood</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Askari 14 Rawalpindi Cantt</address>
        <city>Rawalpindi</city>
        <country1>Pakistan</country1>
        <zip>46000</zip>
        <telephone>+92 321 9114566</telephone>
        <email>saadfcps@gmail.com</email>
        <affiliation>Armed Forces institute of Dentistry CMH Rawalpindi</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients between 18–60 years
Either male or female gender
Cases of complex zygomaticomaxillary fractures involving infra orbital foramen
Cases planned for surgery i.e open reduction and internal fixation</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Concomitant fracture of the maxillofacial skeleton
Pregnant women
Patients on anxiolytics or antidiabetics</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S02.40</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fracture of malar, maxillary and zygoma bones, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Melatonin 10 mg orally at bedtime for 15 days, starting 60–90 minutes before surgery</i_keyword>
      <i_keyword>Control group: Placebo 10 mg orally at bedtime for 15 days, starting 60–90 minutes before surgery</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Postoperative pain. Timepoint: Postoperative day 7. Method of measurement: VAS (0–10).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>National University of Medical Sciences Pakistan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-09-03</approval_date>
        <contact_name>Ethics committee of Armed Forces Institute of Dentistry Rawalpindi</contact_name>
        <contact_address>Armed Forces Institute of Dentistry, CMH Rawalpindi Rawalpindi Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
